Sentynl Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sentynl Therapeutics (US): 3 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $10.7M 2024 CMS Part D & Medicaid spend, and $1,867 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$10.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$10.7M
California HCAI SB 17 FilingsSpecialty launch notice ($1,867 intro WAC)